Search research articles
Contact Us
Filters
Showing results (331-340 of 991) with videos related to
Page
of 100
Sort By:
European Heart Journal
|
August 24, 2018
Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used
Waleed E Ali, George L Bakris
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
Hillel K Sternlicht, George L Bakris
Journal of Internal Medicine
|
February 3, 2026
The urinary albumin-to-creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease
Holly J Kramer, George L Bakris
The American Journal of Medicine
|
July 9, 2010
The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome
Addison A Taylor, George L Bakris
Hypertension (Dallas, Tex. : 1979)
|
March 24, 2004
When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk
George L Bakris, James R Sowers
The Medical Clinics of North America
|
February 12, 2004
What have we learned from the current trials?
Kevin C Abbott, George L Bakris
Journal of Clinical Hypertension (Greenwich, Conn.)
|
November 13, 2004
Comparison of commonly used assays for the detection of microalbuminuria
Douglas E Busby, George L Bakris
Seminars in Nephrology
|
October 6, 2005
Hypertension treatment guidelines: practical implications
Kenneth L Choi, George L Bakris
Kidney International
|
August 3, 2006
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside
P A Sarafidis, G L Bakris
Postgraduate Medicine
|
May 10, 2008
Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression
George L Bakris, Matthew R Weir
Page
of 100
Search research articles
Search
Showing results (331-340 of 991) with videos related to
Sort By:
Page
of 100
European Heart Journal
|
August 24, 2018
Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used
Waleed E Ali, George L Bakris
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
Hillel K Sternlicht, George L Bakris
Journal of Internal Medicine
|
February 3, 2026
The urinary albumin-to-creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease
Holly J Kramer, George L Bakris
The American Journal of Medicine
|
July 9, 2010
The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome
Addison A Taylor, George L Bakris
Hypertension (Dallas, Tex. : 1979)
|
March 24, 2004
When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk
George L Bakris, James R Sowers
The Medical Clinics of North America
|
February 12, 2004
What have we learned from the current trials?
Kevin C Abbott, George L Bakris
Journal of Clinical Hypertension (Greenwich, Conn.)
|
November 13, 2004
Comparison of commonly used assays for the detection of microalbuminuria
Douglas E Busby, George L Bakris
Seminars in Nephrology
|
October 6, 2005
Hypertension treatment guidelines: practical implications
Kenneth L Choi, George L Bakris
Kidney International
|
August 3, 2006
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside
P A Sarafidis, G L Bakris
Postgraduate Medicine
|
May 10, 2008
Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression
George L Bakris, Matthew R Weir
Page
of 100